A Randomized, Double-Blind, Dose-Ranging Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Vitiligo
- Focus Therapeutic Use
- Sponsors Incyte Corporation
- 08 May 2017 Status changed from not yet recruiting to recruiting.
- 04 May 2017 According to an Incyte corporation media release, the company is planning to start this trial in 2017.
- 07 Apr 2017 New trial record